Sutro Biopharma, Inc. (STRO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1236174,
    "name": "Sutro Biopharma, Inc.",
    "stock_name": "Sutro Biopharma, Inc.",
    "full_name": "Sutro Biopharma, Inc.",
    "name_url": "stocks-analysis/sutro-biopharma-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "9.38",
    "chg": 8.65,
    "chgp": "1185.28%",
    "dir": 1,
    "prev_price": "0.73",
    "mcapval": "83.27",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US8693671021",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "528.68 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sutro-biopharma-inc-1236174-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Sutro Biopharma, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sutro-biopharma-inc-technically-bullish-or-bearish-3547197",
        "imagepath": "",
        "date": "2025-09-20 19:49:20",
        "description": "As of 12 September 2025, the technical trend for Sutro Biopharma, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly. Moving averages are mildly bearish on a daily basis, and the KST presents a bullish signal weekly but bearish monthly. Dow Theory shows a mildly bearish weekly trend and a mildly bullish monthly trend. OBV is mildly bullish across both time frames.\n\nIn terms of performance, Sutro Biopharma has significantly underperformed compared to the S&P 500, with a year-to-date return of -50.93% versus the S&P 500's 12.22%, and a one-year return of -77.14% compared to 17.14% for the benchmark...."
      },
      {
        "title": "Is Sutro Biopharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sutro-biopharma-inc-overvalued-or-undervalued-3543625",
        "imagepath": "",
        "date": "2025-09-20 18:24:19",
        "description": "As of 18 March 2021, the valuation grade for Sutro Biopharma, Inc. moved from fair to risky, indicating a deteriorating outlook. The company is overvalued based on its current financial metrics, which include a Price to Book Value of -2.77, an EV to EBIT of -0.09, and an EV to EBITDA of -0.09, all suggesting significant financial distress. In comparison to peers, Sutro's valuation ratios are notably worse; for instance, Akebia Therapeutics, Inc. has a P/E ratio of -30.59, while scPharmaceuticals, Inc. shows an EV to EBITDA of -4.64.\n\nRecent stock performance further underscores this valuation concern, with Sutro Biopharma's year-to-date return at -50.93%, significantly lagging behind the S&P 500's positive return of 12.22%. Over the past year, Sutro has declined by 77.14%, while the S&P 500 has gained 17.14%, reinforcing the notion that the stock is currently overvalued...."
      }
    ],
    "total": 7,
    "sid": "1236174",
    "stock_news_url": "https://www.marketsmojo.com/news/sutro-biopharma-inc-1236174"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Sutro Biopharma, Inc. technically bullish or bearish?

2025-09-20 19:49:20

As of 12 September 2025, the technical trend for Sutro Biopharma, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows a bullish signal on the monthly but no signal on the weekly. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly. Moving averages are mildly bearish on a daily basis, and the KST presents a bullish signal weekly but bearish monthly. Dow Theory shows a mildly bearish weekly trend and a mildly bullish monthly trend. OBV is mildly bullish across both time frames. In terms of performance, Sutro Biopharma has significantly underperformed compared to the S&P 500, with a year-to-date return of -50.93% versus the S&P 500's 12.22%, and a one-year return of -77.14% compared to 17.14% for the benchmark....

Is Sutro Biopharma, Inc. overvalued or undervalued?

2025-09-20 18:24:19

As of 18 March 2021, the valuation grade for Sutro Biopharma, Inc. moved from fair to risky, indicating a deteriorating outlook. The company is overvalued based on its current financial metrics, which include a Price to Book Value of -2.77, an EV to EBIT of -0.09, and an EV to EBITDA of -0.09, all suggesting significant financial distress. In comparison to peers, Sutro's valuation ratios are notably worse; for instance, Akebia Therapeutics, Inc. has a P/E ratio of -30.59, while scPharmaceuticals, Inc. shows an EV to EBITDA of -4.64. Recent stock performance further underscores this valuation concern, with Sutro Biopharma's year-to-date return at -50.93%, significantly lagging behind the S&P 500's positive return of 12.22%. Over the past year, Sutro has declined by 77.14%, while the S&P 500 has gained 17.14%, reinforcing the notion that the stock is currently overvalued....

View All News